2 - Schools incorporating the Life Sciences and Medicine
Permanent URI for this communityhttps://hdl.handle.net/2164/330
Browse
7 results
Search Results
Item Implementing selective digestive tract decontamination in the intensive care unit : A qualitative analysis of nurse-identified considerations(2014-01) Marshall, Andrea P; Weisbrodt, Leonie; Rose, Louise; Duncan, Eilidh; Prior, Maria; Todd, Laura; Wells, Elisabeth; Seppelt, Ian; Cuthbertson, Brian; Francis, Jill; University of Aberdeen.Other Applied Health Sciences; University of Aberdeen.Aberdeen Health Psychology GroupItem A pragmatic randomised, controlled trial of intensive care follow up programmes in improving longer-term outcomes from critical illness : the PRACTICAL study(2007-07-23) Cuthbertson, Brian; Rattray, Janice; Johnston, Marie; Wildsmith, J Anthony; Wilson, Edward; Hernandez, Rodolfo; Ramsay, Craig; Hull, Alastair M; Norrie, John; Campbell, Marion; PRaCTICaL Study Group; University of Aberdeen.Other Applied Health Sciences; University of Aberdeen.Institute of Applied Health SciencesItem Effectiveness and cost-effectiveness of arthroscopic lavage in the treatment of osteoarthritis of the knee: a mixed methods study of the feasibility of conducting a surgical placebo-controlled trial (the KORAL study)(2010-01-01) Campbell, Marion Kay; Skea, Zoe Christina; Sutherland, Alasdair George; Cuthbertson, Brian; Entwistle, Vikki Ann; McDonald, Alison Mary; Norrie, John David Taylor; Carlson, R V; Bridgman, S; KORAL study group; University of Aberdeen.Other Applied Health Sciences; University of Aberdeen.Institute of Applied Health Sciences; University of Aberdeen.Applied Medicine; University of Aberdeen.Aberdeen Centre for EvaluationItem Quality of life in the five years after intensive care : a cohort study(2010-01-20) Cuthbertson, Brian; Roughton, Sian; Jenkinson, David James; MacLennan, Graeme Stewart; Vale, Luke David; University of Aberdeen.Other Applied Health Sciences; University of Aberdeen.Institute of Applied Health SciencesItem Predicting death and readmission after intensive care discharge(Oxford Journals, 2008-06) Campbell, Alison J.; Cook, Jonathan Alistair; Adey, Gillian; Cuthbertson, Brian; University of Aberdeen, School of Medicine & Dentistry, Division of Applied Health SciencesBackground: Despite initial recovery from critical illness, many patients deteriorate after discharge from the intensive care unit (ICU). We examined prospectively collected data in an attempt to identify patients at risk of readmission or death after intensive care discharge. Methods: This was a secondary analysis of clinical audit data from patients discharged alive from a mixed medical and surgical (non-cardiac) ICU. Results: Four hundred and seventy-five patients (11.2%) died in hospital after discharge from the ICU. Increasing age, time in hospital before intensive care admission, Acute Physiology and Chronic Health Evaluation II (APACHE II) score, and discharge Therapeutic Intervention Scoring System (TISS) score were independent risk factors for death after intensive care discharge. Three hundred and eighty-five patients (8.8%) were readmitted to intensive care during the same hospital admission. Increasing age, time in hospital before intensive care, APACHE II score, and discharge to a high dependency unit were independent risk factors for readmission. One hundred and forty-three patients (3.3%) were readmitted within 48 h of intensive care discharge. APACHE II scores and discharge to a high dependency or other ICU were independent risk factors for early readmission. The overall discriminant ability of our models was moderate with only marginal benefit over the APACHE II scores alone. Conclusions: We identified risk factors associated with death and readmission to intensive care. It was not possible to produce a definitive model based on these risk factors for predicting death or readmission in an individual patient.Item Hydrocortisone therapy for patients with septic shock(Massachusetts Medical Society., 2008-01-10) Sprung, Charles L.; Annane, Djillali; Keh, Didier; Moreno, Rui; Singer, Mervyn; Freivogel, Klaus; Weiss, Yoram G.; Benbenishy, Julie; Kalenka, Armin; Forst, Helmuth; Laterre, Pierre-Francois; Reinhart, Konrad; Cuthbertson, Brian; Payen, Didier; Briegel, Josef; CORTICUS Study Group; University of Aberdeen, School of Medicine & Dentistry, Division of Applied Health SciencesBackground Hydrocortisone is widely used in patients with septic shock even though a survival benefit has been reported only in patients who remained hypotensive after fluid and vasopressor resuscitation and whose plasma cortisol levels did not rise appropriately after the administration of corticotropin. Methods In this multicenter, randomized, double-blind, placebo-controlled trial, we assigned 251 patients to receive 50 mg of intravenous hydrocortisone and 248 patients to receive placebo every 6 hours for 5 days; the dose was then tapered during a 6-day period. At 28 days, the primary outcome was death among patients who did not have a response to a corticotropin test. Results Of the 499 patients in the study, 233 (46.7%) did not have a response to corticotropin (125 in the hydrocortisone group and 108 in the placebo group). At 28 days, there was no significant difference in mortality between patients in the two study groups who did not have a response to corticotropin (39.2% in the hydrocortisone group and 36.1% in the placebo group, P=0.69) or between those who had a response to corticotropin (28.8% in the hydrocortisone group and 28.7% in the placebo group, P=1.00). At 28 days, 86 of 251 patients in the hydrocortisone group (34.3%) and 78 of 248 patients in the placebo group (31.5%) had died (P=0.51). In the hydrocortisone group, shock was reversed more quickly than in the placebo group. However, there were more episodes of superinfection, including new sepsis and septic shock. Conclusions Hydrocortisone did not improve survival or reversal of shock in patients with septic shock, either overall or in patients who did not have a response to corticotropin, although hydrocortisone hastened reversal of shock in patients in whom shock was reversed. (ClinicalTrials.gov number, NCT00147004 [ClinicalTrials.gov] .)Item Renal function, revascularization and risk(OUP, 2007) Hillis, Graham S.; Cuthbertson, Brian; Croal, Bernard L.; University of Aberdeen, School of Medicine & Dentistry, Division of Applied Medicine; University of Aberdeen, School of Medicine & Dentistry, Division of Applied Health Sciences